A. A. Shalyova

A. A. Shalyova

Auto-generated profile, based on publicly available information

A. A. Shalyova

Siberian Federal University; Federal Siberian Scientific Clinical Center

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2021 in Russian neurological Journal
Verified
Journal Article
Open access
PDF file
TST. N. Subbotina
T. N. Subbotina
VAV. G. Abramov
V. G. Abramov
ARA. A. Razumova
A. A. Razumova
GKG. Y. Kochmaryova
G. Y. Kochmaryova
AKA. A. Karnyushka
A. A. Karnyushka
ГКГ. Ю. Кочмарева
Г. Ю. Кочмарева
Background. Parkinson’s disease (PD) is one of the common neurodegenerative diseases. Several genes are known (SNCA, PARK2, PINK1, PARK7 (DJ-1) and LRRK2), mutations in which have a pathological significance in the development of monogenic PD; association with PD of other genes (for example, UCHL1, ATP13A2) requires further study. It is also known, that GBA gene is associated with an increased risk of PD developing.Aim. Analysis of mutations and polymorphisms in the PARK2, PINK1, SNCA, ATP13A2, PARK7, LRRK2, UCHL, GCH1 and GBA genes in patients with PD from Krasnoyarsk region.Material and methods. The 60 patients with sporadic and familial forms of PD were included in the study. The SALSA MLPA Holland P051 and P052 kits («MRC Amsterdam», The Netherlands) were used to detect deletions and duplications in the PARK2, PINK1, SNCA, ATP13A2, PARK7, LRRK2, UCHL, GCH1 genes, as well as point mutations A30P in the SNCA gene and G2019S in the LRRK2 gene. Analysis of the GBA gene was carried out by Senger sequencing.Results. None of the 60 patients had mutations that were searched with the SALSA MLPA Holland P051 and P052 kits. 6 different mutations in the GBA gene were found in 9 out of 60 patients with PD. L444P («severe» PD — associated mutation) — in two patients, D409H («severe» PD — associated mutation) — in one patient, T369M (polymorphism, possibly associated with PD) — in two patients, E326K (polymorphism, possibly associated with PD) — in one patient, V460V (synonymous variant, which is part of the composition of the complex RecNcil mutation (p.L444P; p.A456P; p.V460V) associated with PD) — in two patients and variant C.*92g>A (3’ — UTR polymorphism, possibly associated with PD) — in one patient. Two patients had compound heterozygous carriers of two variants.Conclusion. This paper presents the genetic analysis results of the PD associated genes among patients from the Krasnoyarsk region. No mutations were detected in the PARK2, PINK1, SNCA, ATP13A2, PARK7, LRRK2, UCHL and GCH1 genes. Genetic variants analysis of the GBA gene showed similar frequency in the patients from the Krasnoyarsk region as in European populations.

27 January 2024 in Oncohematology
Verified
Journal Article
Open access
PDF file
TST. N. Subbotina
T. N. Subbotina
ASA. A. Shalyova
A. A. Shalyova
ASA. I. Shevchenko
A. I. Shevchenko
EPE. A. Pozdysheva
E. A. Pozdysheva
YVYa. A. Voytsekhovskaya
Ya. A. Voytsekhovskaya
KMKonstantin Mironov
Konstantin Mironov
Background. According to WHO guidelines, one of the criteria for diagnosis of polycythemia vera is the presence of somatic mutations in exon 12 of the JAK2 gene, but to date there is no universally accepted simple method to analyze these mutations. We have previously proposed two methods for screening such mutations based on heteroduplex and HRM (High Resolution Melt) assays, which are relatively cheap and fast compared to sequencing.Aim. To analyze the sensitivity of these screening methods.Materials and methods. The study used cloned DNA samples from 6 patients with various mutations in exon 12 of the JAK2 gene that we had previously identified, as well as a clone of the corresponding wild-type DNA segment. Dilution of the cloned mutant samples with wild-type clones was performed to obtain samples with different levels of allele burden: 100, 50, 25, 12.5, 6.25, 3.13, 1.56 and 0.78 %. Heteroduplex analysis followed by PAGE (polyacrylamide gel) and HRM analysis was then performed with the diluted samples.Results. The sensitivity threshold of the heteroduplex analysis was found to be between 3.13–6.25 % allele burdens depending on the specific mutation, the sensitivity threshold of the HRM assay was 6.25–12.5 % similarly.Conclusion. Our proposed methods of heteroduplex analysis followed by PAGE and HRM-analysis for the detection of polycythemia vera-specific mutations in exon 12 of the JAK2 gene allow increasing the efficiency of using different types of sequencing and can be used as simpler and less expensive methods of preliminary screening of these mutations.

21 April 2023 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
TST.N. Subbotina
T.N. Subbotina
VAV.G. Abramov
V.G. Abramov
ASA.A. Shaleva
A.A. Shaleva
SVS.V. Vereschagina
S.V. Vereschagina
DPD.V. Pokhabov
D.V. Pokhabov
ЦЕЛЬ ИССЛЕДОВАНИЯ Анализ мутаций и полиморфизмов во 2, 7, 8, 9, 10 и 11-м экзонах гена GBA у пациентов Красноярского региона с болезнью Паркинсона (БП). МАТЕРИАЛ И МЕТОДЫ Обследованы 75 пациентов со спорадической и семейной формами БП. Материалом для исследования гена GBA являлась геномная ДНК, выделенная из цельной крови пациентов. Анализ вышеуказанных экзонов гена GBA проводился методом секвенирования по Сенгеру. РЕЗУЛЬТАТЫ Различные изменения в структуре ДНК гена GBA были выявлены у 11 пациентов, таким образом, общая частота встречаемости вариантов в GBA составила 14,7%, а частота патологически значимых мутаций (p.L444P, p.D409H, p.H255Q) — 5,3%. ЗАКЛЮЧЕНИЕ Представленность вариантов в гене GBA, одном из наиболее распространенных факторов высокого риска развития БП, у пациентов Красноярского региона оказалась достаточно высока и сопоставима с таковой у пациентов в других популяциях мира. Таким образом, скрининг мутаций в гене GBA актуален для пациентов с БП, проживающих в Красноярском регионе, в рамках генетического консультирования в настоящее время, и в будущем, возможно, будет необходим для персонализированного лечения.

15 March 2023 in Oncohematology
Verified
Journal Article
Open access
PDF file
TST. N. Subbotina
T. N. Subbotina
IMI. E. Maslyukova
I. E. Maslyukova
KSK. S. Semashchenko
K. S. Semashchenko
GKG. A. Khodos
G. A. Khodos
DKD. V. Kurochkin
D. V. Kurochkin
KMKonstantin Mironov
Konstantin Mironov
Background. The development of myelofibrosis (MF) is driven by complex molecular genetic events that include driver somatic mutations responsible for the constitutive activation of the JAK/STAT signaling pathway (JAK2, CALR, and MPL), additional mutations affecting epigenetic regulators (TET2, ASXL1, IDH1/2, etc.) and RNA splicing (SRSF2, U2AF1, SF3B1, etc.), as well as genetic aberrations that contribute to genomic instability and disease progression.Aim. To analyze driver (JAK2, CALR, MPL) and prognostic (ASXL1) somatic mutations in patients with MF and evaluate their impact on survival.Materials and methods. The study included 29 patients diagnosed with MF, selected by hematologists from the City Clinical Hospital No. 7 and Regional Clinical Hospital (Krasnoyarsk).Results. 26 (89.6 %) out of 29 examined patients had some driver mutations in JAK2, CALR, MPL genes. The p.V617F mutation in the JAK2 gene was found in 20 (68.9 %) patients. Mutations in the CALR gene were detected in 4 (13.8 %) patients, mutations in the MPL gene were found in 3 patients (10.3 %). In 1 of 26 patients, 2 driver mutations were present simultaneously. 3 (10.3 %) patients were triple negative. Mutations in the ASXL1 gene were detected in 12 (41.4 %) out of 29 examined patients. Conducted targeted NGS (next generation sequencing) for 13 out of 29 patients revealed additional genetic variants that contribute to the understanding of the development mechanism and disease course. When evaluating the overall survival in the groups of patients diagnosed with MF examined by us, depending on the combination of driver (JAK2, CALR, MPL) and prognostic (ASXL1) mutations, no statistically significant differences were found (p = 0.12). This appears to be due to the small sample size. At the same time, assessment of patient survival depending on ASXL1 status showed that in the presence of mutations in the ASXL1 gene, the median survival was 45 months (range 7–120 months), while in the absence of mutations it was 48 months (range 21–359 months) (p = 0.03).Conclusion. The results obtained allow us to assume that the presence of mutations in the ASXL1 gene is an unfavorable factor in the course of the disease.

28 December 2023 in Russian journal of hematology and transfusiology
Verified
Journal Article
Open access
PDF file
TST. N. Subbotina
T. N. Subbotina
ASA. A. Shalyova
A. A. Shalyova
GKG. A. Khodos
G. A. Khodos
NON. V. Oreshkova
N. V. Oreshkova
MMM. A. Mikhalev
M. A. Mikhalev
KMKonstantin Mironov
Konstantin Mironov
Introduction. In addition to the clonal nature of the development of erythrocytosis, there are other causes, such as germinal mutations in genes of proteins responsible for the development of familial inherited erythrocytosis (EPOR, VHL, EPAS1, EGLN1, etc.).Aim. To conduct the analysis of mutations in the EPOR, VHL, EPAS1 and EGLN1 genes associated with the familial erythrocytosis ECYT1-4 among JAK2- and CALR-negative patients.Materials and methods. The study included 50 JAK2- and CALR-negative patients of Krasnoyarsk Krai with erythrocytosis of unclear etiology. Analysis of mutations in the EPOR, VHL, EPAS1 and EGLN1 genes, responsible for the development of familial erythrocytosis was conducted with the use of the Sanger sequencing. A mass parallel sequencing study was also performed for 12 patients.Results. The Sanger sequencing analysis of EPOR, VHL, EPAS1 and EGLN1 revealed any of the genetic variants in 22 of the 50 patients studied. Of all the variants identifi ed in the coding regions of the genes surveyed that result in amino acid substitutions, the following were of biggest interest: 1) two mutations in the VHL gene (rs28940298 and rs5030821) associated with the development of Chuvash polycythemia (ECYT2); 2) rs12097901 variant in the EGLN1 gene associated with altitude adaptation and increasing haemoglobin levels, but with no pathogenetic relevance for erythrocytosis according to ClinVar; and 3) one mutation in the EPOR gene not previously described in literature. According to the results of the NGS study, 12 somatic and 4 putative germinal variants were identifi ed in 5 out of 12 patients.Conclusion. The possibility of conducting a comprehensive molecular genetic study in order to identify new mutations or those already described in the literature in genes associated with familial erythrocytosis could make a signifi cant contribution to the diagnosis of patients with absolute erythrocytosis.

24 August 2026 in Extreme Medicine
Verified
Journal Article
Open access
PDF file
ASA. A. Shalyova
A. A. Shalyova
TST. N. Subbotina
T. N. Subbotina
SPS. A. Pipparinen
S. A. Pipparinen
VAV. G. Abramov
V. G. Abramov
АША. А. Шалева
А. А. Шалева
ВАВ. Г. Абрамов
В. Г. Абрамов
Association of the rs242557 and rs7521 variants in the MAPT gene with the development of Parkinson’s disease | Shalyova | Extreme Medicine Ассоциация вариантов rs242557 и rs7521 в гене MAPT с развитием болезни Паркинсона | Шалева | Экстремальная биомедицина